-
Featured
Immunotherapies to Treat Glioblastoma
William T. Curry, MD, co-director of Mass General Neuroscience and director of Neurosurgical Oncology in the Department of Neurosurgery at Massachusetts General Hospital, discusses a four-center trial studying the use of poliovirus to treat malignant brain tumors.
-
Recent Advances in the Use of Neoadjuvant Immunotherapy in Melanoma
Multiple trials have shown the advantages of adjuvant immunotherapy in patients with high-risk, resectable melanoma. Sonia Cohen, MD, PhD, a surgical oncologist at the Mass General Brigham Cancer Institute, explains why she is now employing neoadjuvant immunotherapy to manage this patient population.
-
ROS-Sensing Pathway Influences Mitochondrial Activity, Regulates Response to Cisplatin
Liron Bar-Peled, PhD, and colleagues have determined that mitochondrial function is pivotal to chemotherapy response and may help identify tumors that are sensitive to subtypes of chemotherapeutic agents.
-
Ultrasound Can Identify Subclinical Musculoskeletal Toxicity of Cancer Checkpoint Inhibitor Therapy
Massachusetts General Hospital physicians found that among 34 patients with new musculoskeletal symptoms during checkpoint inhibitor therapy, ultrasound identified inflammation in 10 of 14 patients without clinically evident synovitis and in all seven whose synovial fluid cell counts were in the non-inflammatory range.
-
Revealing the Mechanisms of CAR T-Cell Therapy Resistance in Solid Tumors
Physician-scientists at Massachusetts General Hospital use patient-derived tumor models to decode mechanisms of CAR T-cell therapy resistance in solid tumors.
-
Revolutionizing Cancer Immunotherapy for Melanoma and Beyond
Researchers at Massachusetts General Hospital won a Breakthrough Award to enhance personalized approaches to immunotherapy for metastatic melanoma.
Immunotherapy Contributors
-
Areej R. El-Jawahri, MD
Co-Director, Cancer Outcomes Research and Education Program, Director, Bone Marrow Transplant Survivorship Program, Mass General Brigham Cancer Institute, Professor of Medicine, Harvard Medical School
Recent Article
Digital App Improves Quality of Life for Caregivers of Patients Undergoing HSCT
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Brigham Cancer Institute, Professor of Pathology, Harvard Medical School
Recent Article
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
-
Justin Gainor, MD
Director, Center for Thoracic Cancers Program, Director of Targeted Immunotherapy, Mass General Brigham Cancer Institute, Associate Professor of Medicine, Harvard Medical School
Recent Article
Molecular Features Identified That Predict Response to Checkpoint Inhibitors in NSCLC
-
Michael L. Dougan, MD, PhD
Physician, Division of Gastroenterology, Massachusetts General Hospital, Director, GI Center for Cancer Complications, Mass General Cancer Center, Preclinical Education Group Leader, Associate Professor of Medicine, Harvard Medical School
Recent Article
Case Series: Tofacitinib Is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology, Massachusetts General Hospital, Adeline Rose Wydotis Professor of Neurosurgery, Harvard Medical School
Recent Article
Review: The Role of Antibody-Based Therapies in Neuro-Oncology
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.